EUVIMEDEUVIMED entdecken
Crossref

Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy

Yu-De Chu iD, Chao-Wei Hsu, Pei-Huan Ho, Chih-Yung Chiou, Chih-Lang Lin, Kung-Hao Liang iD, Ming-Wei Lai, Chau-Ting Yeh

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.16791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Yu-De Chu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liver Research Center, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B virus, Antiviral Agents, Guanine, Hepatitis B, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Science and Technology Council, Taiwan, Linkou Chang Gung Memorial Hospital, Taiwan, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Hepatitis B virus (HBV) reactivation could develop after withdrawal following a finite course of nucleoside analog (NA) therapy, leading to virological and clinical relapses. The genetic heterogeneity in the HBV surface and polymerase genes during finite NA therapy has not been carefully studied.

Methods

Seven chronic HBV‐infected patients experiencing relapses following entecavir (ETV; n = 5; Patients 1 to 5) or tenofovir disoproxil fumarate (TDF; n = 2; Patients 6 and 7) withdrawal were included. Sera obtained before treatment and at relapses were retrieved and submitted for DNA extraction and amplicon‐specific deep sequencing.

Results

ETV‐treated patients had a longer time‐to‐relapse than that of TDF‐treated patients ( P = 0.0357). No drug‐resistance related polymerase mutation was detected during relapses, except for a low percentage (1.4%) of rtM204I mutation in Patient 1. Two surface truncation mutations (sW216*; 40.9% and sW182*; 4.7%) detected before treatment in two TDF‐treated patients (Patients 6 and 7, respectively) were overtaken by the wild types during subsequent drug‐withdrawal‐related relapses. The simultaneous presence of sG44E (T‐cell epitope) and sE164G (B‐cell epitope) mutations was associated with failure of HBV e antigen (HBeAg) seroclearance in ETV‐treated patients.

Conclusions

In conclusion, HBV genome continues to evolve during the courses of finite antiviral therapies. Pre‐existing surface truncation mutations can be overtaken by the wild types after relapses. The sG44E/sE164G mutations are associated with failure of HBeAg seroclearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusAntiviral AgentsGuanineHepatitis B, ChronicHepatitis B Surface AntigensEvolution, MolecularGene Products, polHumansMaleMiddle AgedMutationFemaleAdultTenofovirRecurrenceDrug Resistance, ViralVirus ActivationDNA, Viral

Stichwörter der Autor:innen

deep sequencingentecavirquasispeciesreverse transcriptasesurface antigen escape mutanttenofovir disoproxil fumarate

Substanzen

Antiviral AgentsentecavirGuanineTenofovirHepatitis B Surface AntigensGene Products, polDNA, Viral

Autor:innen und Institutionen

  • Liver Research Center, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan.
  • Department of Hepatology and Gastroenterology, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan.
  • Liver Research Unit and Community Medicine Research Center, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Medical Research Department, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Pediatrics, Division of Pediatric Gastroenterology, Liver Research Center, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan.
  • Institute of Stem Cell and Translational Cancer Research, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.

ORCID-Profile: Yu-De Chu, Kung-Hao Liang

Förderung

  • National Science and Technology Council, Taiwan
  • Linkou Chang Gung Memorial Hospital, Taiwan
  • National Science and Technology Council

Zitieren

APA

Chu, Y. D., Hsu, C. W., Ho, P. H., Chiou, C. Y., Lin, C. L., Liang, K. H., Lai, M. W., & Yeh, C. T. (2025). Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16791

Vancouver

Chu YD, Hsu CW, Ho PH, Chiou CY, Lin CL, Liang KH, et al. Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16791

BibTeX
@article{Chu2025,
  author = {Chu, Yu-De and Hsu, Chao-Wei and Ho, Pei-Huan and Chiou, Chih-Yung and Lin, Chih-Lang and Liang, Kung-Hao and Lai, Ming-Wei and Yeh, Chau-Ting},
  title = {Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.16791}
}
Kostenlos starten →